Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WSK-V106
- Development stage
- Unknown
- Lead developer
- Chengdu Weisk Biopharmaceutical
- Modality
- Recombinant Proteins and Enzymes, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
WSK-V106 is a recombinant protein COVID-19 vaccine, specifically a trivalent (XBB+BA.5+Delta) genetically engineered subunit vaccine developed for use as a booster in adults who have previously received two or three doses of other COVID-19 vaccines. It is produced using Sf9 insect cells and targets the SARS-CoV-2 spike (S) protein to stimulate an immune response, acting both as an inhibitor of viral entry and as an immunostimulant to promote protective immunity against multiple SARS-CoV-2 variants. The vaccine is being developed by Chengdu Weisk Biopharmaceutical Co., Ltd., in collaboration with West China Hospital, and has reached Phase 3 clinical trials for booster vaccination in adults[2][3].
- Brand names
- Coviccin
- Other names
- 威克欣WestVac Omicron vaccinerecombinant COVID-19 vaccine (Sf9 cells)
02
Targets
BVDV E2 (Bovine viral diarrhea virus glycoprotein E2)
Beyond the preview
Go deeper on WSK-V106.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WSK-V106.